---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-019249"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:50:16.804063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics reports FY2023 net loss of $64.5M; cash runway through Q3 2025 on $50M Feb 2024 offering

## Summary
- Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).
- Cash and equivalents $86.9M at Dec 31, 2023; Feb 2024 $50M offering extends runway through Q3 2025.
- BEACON Phase 1b/2a in CSU enrolling; initial data from first four cohorts expected Q3 2024.
- SPOTLIGHT Phase 1b/2a in CIndU approved; data expected H2 2024.
- Phase 1 trial in LR-MDS initiated; initial data anticipated mid-2024.

## SEC filing metadata
- accession: 0001213900-24-019249
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/0001213900-24-019249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/ea0201079-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-019249
- JSON: https://secwatch.observer/filing/0001213900-24-019249.json
- Plain text: https://secwatch.observer/filing/0001213900-24-019249.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: net income $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18, EPS $6.18.
  - Period: fiscal year ended December 31, 2023
  - Net income: $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18
  - EPS: $6.18
  - Result: reported results
  source text: Jasper reported a net loss of $16.6 million and $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $1.50 and $6.18, for the three months and the year ended December 31, 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/0001213900-24-019249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.